Dr Irmgard Irminger-Finger is the founder and co-inventor of BARD1 Life Sciences and its technology. She has more than 15 years of experience in biotech as founder, director, chair, recipient of Swiss startup awards, and one of five finalists in the 2014 European Woman Entrepreneur Award. She is an internationally recognised expert in tumour biology with over 100 publications, multiple international collaborations and many keynote presentations at international conferences. Dr Irminger-Finger has a Masters degree in molecular biology and a PhD in molecular genetics from the University of Zurich, and was an award research fellow at the Harvard University. She holds a tenured faculty position at the University (UNIGE) and University Hospital of Geneva (HUG), and Adjunct Professorship at the University of Western Australia.